Resonant Therapeutics announced it has entered an agreement with Janssen R&D with an aim to discover and develop tumor and immunological targets, and to validate certain therapeutic candidates.
The agreement will see Janssen gain access to Resonant’s Integrated Microenvironment Pathway Catalog and Triage (Impact) tumor microenvironment model and target validation platform.
Resonant won a Johnson & Johnson Innovation award after its participation at the JLABS @ TMC QuickFire Challenge in 2016, which allowed the company to join the JLABS life science incubator program, supported by J&J.
The company’s Impact platform has the potential to enable discovery of ‘unappreciated’ targets and ‘functionally active’ anti-tumor antibodies to develop therapeutic candidates for difficult to treat tumors, according to Resonant.
More specifically, the company stated that its “live cell, function-first approach lets the tumor cells, microenvironment, and live animal immune systems do the work of target and therapeutic candidate identification and validation.”
“Specific tumor microenvironment factors are critical to the malignant cell state, but are not present in traditional discovery models,” the company added.
According to Resonant, the platform has already resulted in a generation of therapeutic antibodies which “have not and would not have been discovered by other methods.”
